Nephrocare Health Services
Market cap ₹6,567 Cr
- P/E
- 53.57
- Day range
- ₹648.40 – ₹690.95
- 52-week range
- ₹446.00 – ₹781.50
- Volume
- 3.39 L
- Open
- ₹663.35
- Prev close
- ₹667.75
Latest results · Q2 FY27(consolidated)Revenue ₹303 CrProfit ₹34 CrMargin 11.1%YoY vs the same quarter last year
1 red flag to read up on
- medium
Promoter holding falling
58.31%, down 5.54 pts since 2025-12-16 · 30 Sept 2026
From NSE and BSE filings. A flag is a reason to read the filing, not a rating.
NEPHROPLUS in NSE indices and F&O
Research profile
Composite 54 / 100Factor percentiles
Derived metrics
- Earn. yield
- 1.9%
- Graham no.
- ₹185.47
- vs Graham
- -71.6%
- ROE ÷ P/B
- 1.7%
- Magic Formula
- #478
- FCF yield
- 1.7%
Appears in 8 scans
Percentiles rank this stock against the other tracked stocks and change as they do. Scans describe where figures sit today. Hover a label for its definition. Not investment advice.
Peer comparison
All 68 in Pharma| Company | M-cap | P/E | P/B | ROE | ROCE | OPM | D/E | Sales YoY |
|---|---|---|---|---|---|---|---|---|
| Sun PharmaSUNPHARMA | ₹4.49 L Cr | 40.95 | 5.03 | 14.8% | 21.0% | 29.0% | 0.04 | +11.9% |
| Divi's LaboratoriesDIVISLAB | ₹2.93 L Cr | 87.19 | 16.88 | 16.2% | 22.0% | 43.0% | 0.00 | +35.4% |
| Torrent PharmaTORNTPHARM | ₹1.75 L Cr | 77.88 | 9.67 | 26.8% | 15.0% | 33.0% | 0.77 | +50.8% |
| Apollo HospitalsAPOLLOHOSP | ₹1.27 L Cr | 56.40 | 11.55 | 22.6% | 17.0% | 16.0% | 0.77 | +23.0% |
| Laurus LabsLAURUSLABS | ₹1.25 L Cr | 93.72 | 19.82 | 18.2% | 18.0% | 34.0% | 0.43 | +33.5% |
| Zydus LifesciencesZYDUSLIFE | ₹1.20 L Cr | 28.72 | 4.32 | 20.1% | 21.0% | 24.0% | 0.50 | +29.2% |
| Dr. Reddy's LabsDRREDDY | ₹1.17 L Cr | 41.63 | 2.97 | 11.6% | 13.0% | 20.0% | 0.19 | -1.5% |
| Nephrocare Health ServicesNEPHROPLUS | ₹6,567 Cr | 53.57 | 5.44 | 9.1% | 15.0% | 21.0% | 0.13 | +23.2% |
| Sector median | ₹24,603 Cr | 43.68 | 5.46 | 15.1% | 17.0% | 24.0% | 0.17 | +22.7% |
Sector as classified in the tracked universe; medians use every tracked Pharma company, and P/E only profitable ones. Tinted figures beat the median.
Latest news
Updated 1h agoHeadlines about Nephrocare Health Services from the last two weeks in the financial press. Stories belong to their publishers; Rajat Finance does not endorse them.
Key metrics
- P/E (TTM)
- 50.4
- Price / Book
- 5.53
- ROE (FY26)
- 9.1%
- ROCE (latest year)
- 15%
- Dividend yield
- 0.00%
Moving averages (NSE)
- 20-day
- ₹624.21
- Price above
- 50-day
- ₹659.57
- Price below
- 200-day
- ₹625.82
- Price above
Charts & trends
From company filings. Amounts in ₹ crore.
Revenue, profit & margin - quarterly
₹ crore; a loss shows red. Operating margin below, same periods.
- Revenue
- Net profit
Operating margin
Who owns the company
% of equity by quarter, latest Sept 2026
- Promoter
- Public
- FII
- DII
Cash flows
Where cash came from and went, by fiscal year (₹ crore)
- Operating
- Investing
- Financing
- Free cash flow
Return on equity
Net profit over shareholders' equity, by fiscal year
Equity vs debt
Shareholders' equity against borrowings (₹ crore); the ratio below, same years.
- Equity
- Debt
Debt to equity
Financial statements
| Line item | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 197 | 219 | 228 | 246 | 260 | 266 | 282 | 303 |
| Expenses | 153 | 168 | 180 | 182 | 199 | 215 | 221 | 240 |
| Operating Profit | 44 | 51 | 48 | 64 | 61 | 51 | 60 | 63 |
| OPM % | 22% | 23% | 21% | 26% | 23% | 19% | 21% | 21% |
| Other Income | 5 | 4 | 7 | 4 | 3 | 12 | 7 | 8 |
| Interest | 5 | 6 | 6 | 45 | 6 | 3 | 2 | 3 |
| Depreciation | 18 | 19 | 20 | 23 | 22 | 26 | 25 | 28 |
| Profit before tax | 26 | 30 | 29 | -1 | 36 | 33 | 41 | 40 |
| Tax % | 24% | 17% | 17% | 1427% | 11% | 9% | 22% | 17% |
| Net Profit | 20 | 25 | 24 | -9 | 32 | 30 | 32 | 34 |
| EPS in Rs | ₹2.17 | ₹2.68 | ₹2.56 | ₹-1.02 | ₹3.21 | ₹3.03 | ₹3.19 | ₹3.33 |
From company filings, updated 17 Nov 2026. Consolidated figures where the company reports them. Information only, not investment advice.
Working-capital cycle
+15 days since Mar 2021
+2 days since Mar 2021
+7 days since Mar 2021
+6 days since Mar 2021
+16 days since Mar 2021
Strengths, risks & growth
Incorporated in 2010, Nephrocare Health Services Ltd. provides end-to-end dialysis care through a wide network of clinics across India and select international markets. [1]
Strengths
- Company has reduced debt.
- Company has delivered good profit growth of 162% CAGR over last 5 years
Risks
- Stock is trading at 5.43 times its book value
- Though the company is reporting repeated profits, it is not paying out dividend
- Promoter holding has decreased over last quarter: -5.53%
- Company has a low return on equity of 10.2% over last 3 years.
Compounded Sales Growth
- 10 Years
- —
- 5 Years
- +28%
- 3 Years
- +32%
- TTM
- +25%
Compounded Profit Growth
- 10 Years
- —
- 5 Years
- +162%
- 3 Years
- +103%
- TTM
- +116%
Return on Equity
- 10 Years
- —
- 5 Years
- +6%
- 3 Years
- +10%
- Last Year
- +9%
Strengths and risks are a machine-generated checklist, not advice; growth is compounded annually over each period.
Shareholding pattern
| Holder | Dec 2025 | Mar 2026 | Jun 2026 | Sept 2026 | Change |
|---|---|---|---|---|---|
| Promoter | 63.85% | 63.85% | 63.85% | 58.32% | -5.53 pp |
| FII | 9.30% | 9.94% | 8.78% | 11.73% | +2.95 pp |
| DII | 8.10% | 8.64% | 9.05% | 8.11% | -0.94 pp |
| Public | 18.74% | 17.56% | 18.30% | 21.85% | +3.55 pp |
Filed with NSE for Sept 2026: promoters 58.31%, public 41.69%
Analysts & fund holdings
Who holds the shares, quarter by quarter
Mutual funds 3.93% (+0.73 pp)- Promoters58.3%
- Foreign institutions11.7%
- Mutual funds3.9%
- Insurance0.5%
- Other domestic institutions3.7%
- Retail6.4%
- Others15.4%
| Fund | % of company | % of fund | 3-month change |
|---|---|---|---|
| SBI Healthcare Opp Fund | 0.92% | 1.01% | -0.19 pp |
| DSP Healthcare Fund | 0.60% | 1.05% | -0.14 pp |
| Bandhan Innovation Fund | 0.41% | 0.84% | +0.84 pp |
| Bandhan Small Cap Fund | 0.39% | 0.07% | +0.07 pp |
| LIC MF Infra Fund | 0.38% | 2.24% | +2.24 pp |
Scorecard
- Performance
- Low
- Valuation
- High
- Growth
- Low
- Profitability
- High
- Entry point
- Good
- Red flags
- Low
Analyst coverage, holdings and scorecard from market data; not a recommendation by Rajat Finance.
Risk & trend
From 226 daily sessions to 18 Nov 2026.
Risk
- Volatility (1Y)
- 40.4%
- Downside volatility
- 34.7%
- Worst 5% of days
- 4.0%
- Average of that tail
- 4.8%
- Max drawdown (1Y)
- 22.1%
- Below its peak
- 14.7%
Against the market
- Beta vs Nifty 50
- 0.59
- Correlation
- 0.22
- Relative strength (3M)
- -9.9%
- ATR (14)
- 3.9%
Return
- Return 1M
- +6.3%
- Return 3M
- -6.0%
- Return 6M
- +1.4%
- Return 1Y
- —
- vs 200-day average
- +4.3%
Momentum
- RSI (14)
- 55.6
- MACD histogram
- 7.43
- Stochastic %K
- 64.0
- ADX (14)
- 27.1
- +DI / −DI
- 26.3 / 15.8
- Money flow index
- 50.4
Participation
- Delivery (20d avg)
- 47.8%
- vs its 60-day baseline
- -4.9 pts
- Volume vs 20-day
- +2.1σ
- Close vs day's VWAP
- -2.9%
- 52-week position
- 64 / 100
These describe what this stock's price has already done. They are not forecasts, signals or recommendations, and a dash means the figure was withheld for want of enough history rather than being zero.
Financial quality
From consolidated statements to 30 Sept 2026.
No F-Score: it needs two reporting periods a year apart that carry both an income statement and a balance sheet, and this company's filings do not yet line up that way. The ratios below need only the one period and are unaffected.
- Free cash flow
- ₹113 Cr
- FCF yield
- 1.7%
- Net debt
- -₹64 Cr
- Net debt / equity
- -0.05
- EV / sales
- 5.86
Computed from filed statements, not filed themselves. A dash means an input was absent, and the score counts only the criteria that could actually be tested.
Corporate actions
Company announcements
We hereby inform that the Company has approved grant of ESOPs under the Scheme as per the disclosure annexed herewith.
Pursuant to Reg 30 of SEBI Listing Regulations, 2015, we hereby inform that the Company has approved allotment of 3,42,130 equity shares of Rs. 2/- each, pursuant to the exercise of stock ....
Please find enclosed herewith Transcripts for the Investors Earnings call held on November 4, 2026.
Pursuant to Reg 30 of the SEBI Listing Regulations, we hereby inform you that the Company has scheduled an investor conference call as per the disclosure annexed herewith.
In Continuation to our letter dated October 21, 2026 please find enclosed link of the audio recording of the Investors' Conference Call held on November 04, 2026 on the Unaudited Standalone ....
Please find attached monitoring agency report for the quarter ended September 30, 2026.
Please find investor presentation for quarter and half year ended September 30, 2026.
Press release on Unaudited standalone and consolidated financial results for quarter and half year ended September 30, 2026.
Outcome of the Board meeting held on November 3, 2026 for considering and approving the financial results for the period ended September 30, 2026.
Pursuant to Reg 30 of SEBI Listing Regulations, we wish to hereby inform that the tax assessment order against the Company's overseas wholly-owned subsidiary has been declared invalid ....
Pursuant to Reg 30 of SEBI Listing Regulations, we hereby inform you that Nephrocare Health Services, Philippines Inc., a step-down wholly owned subsidiary of the company has acquired a ....
Pursuant to Reg 30 of the SEBI Listing Regulations, we hereby inform you that the Company has scheduled an investor conference call as per the disclosure annexed herewith.
Nephrocare Health Services Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 03/11/2026 ,inter alia, to consider and approve the Unaudited Standalone ....
We are enclosing herewith a certificate under Reg 74(5) of SEBI (DP) Regulations, 2018 for quarter ended 30th September, 2026 received from M/s. KFIN Technologies Limited.
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Polar Capital Funds PLC
Filed with BSE (scrip 544647); the last 45 days. Documents open at bseindia.com.
Documents
Earnings calls
- Nov 2026TranscriptRecording
- Nov 2026SlidesRecording
- Aug 2026TranscriptSlidesRecording
- May 2026TranscriptSlidesRecording
- Feb 2026TranscriptSlidesRecording
Credit ratings
- Rating update · 20 Jun 2025 from fitch
- Rating update · 22 Mar 2024 from fitch
- Rating update · 30 Dec 2022 from fitch
Documents open at BSE or the rating agency that issued them.
Sourced from the company's NSE XBRL filing dated 4 Nov 2026 (unaudited). View the source filing. Figures are as filed and are not investment advice.
Nephrocare Health Services: common questions
Answered from the figures on this page.